Literature DB >> 23779250

[Early treatment diabetic retinopathy study (ETDRS) visual acuity].

R Told1, M Baratsits, G Garhöfer, L Schmetterer.   

Abstract

Human visual acuity is used as an indicator in everyday clinical work and ophthalmological studies to decide on therapy indications and success. This extensively used parameter needs a very structured workflow in order to preserve validity and prevent bias. Therefore, it should be kept in mind that especially in clinical studies investigators should strictly adhere to the study protocol. The intention of this article is to impart interesting facts about the early treatment diabetic retinopathy study (ETDRS) on visual acuity assessment, adhering to the original protocol of the ETDRS dating back to 1979-1989. Furthermore, the history of visual acuity assessment protocols prior to ETDRS, namely those of Snellen and Bailey-Lovie and finally the logMAR system will be discussed.

Entities:  

Mesh:

Year:  2013        PMID: 23779250     DOI: 10.1007/s00347-013-2813-2

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  18 in total

1.  Letter legibility and chart equivalence.

Authors:  C W McMonnies; A Ho
Journal:  Ophthalmic Physiol Opt       Date:  2000-03       Impact factor: 3.117

2.  CONTOUR INTERACTION AND VISUAL RESOLUTION: CONTRALATERAL EFFECTS.

Authors:  M C FLOM; G G HEATH; E TAKAHASHI
Journal:  Science       Date:  1963-11-15       Impact factor: 47.728

3.  Clinical grading and the effects of scaling.

Authors:  I L Bailey; M A Bullimore; T W Raasch; H R Taylor
Journal:  Invest Ophthalmol Vis Sci       Date:  1991-02       Impact factor: 4.799

4.  Repeatability of visual acuity measurement.

Authors:  T W Raasch; I L Bailey; M A Bullimore
Journal:  Optom Vis Sci       Date:  1998-05       Impact factor: 1.973

5.  Visual acuity scored by the letter-by-letter or probit methods has lower retest variability than the line assignment method.

Authors:  M E Vanden Bosch; M Wall
Journal:  Eye (Lond)       Date:  1997       Impact factor: 3.775

6.  Standardizing the measurement of visual acuity for clinical research studies: Guidelines from the Eye Care Technology Forum.

Authors:  F L Ferris; I Bailey
Journal:  Ophthalmology       Date:  1996-01       Impact factor: 12.079

7.  Ranibizumab for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

8.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

Authors:  Daniel F Martin; Maureen G Maguire; Gui-shuang Ying; Juan E Grunwald; Stuart L Fine; Glenn J Jaffe
Journal:  N Engl J Med       Date:  2011-04-28       Impact factor: 91.245

9.  Prospective evaluation of visual acuity assessment: a comparison of snellen versus ETDRS charts in clinical practice (An AOS Thesis).

Authors:  Peter K Kaiser
Journal:  Trans Am Ophthalmol Soc       Date:  2009-12

10.  Intersession repeatability of visual acuity scores in age-related macular degeneration.

Authors:  Praveen J Patel; Fred K Chen; Gary S Rubin; Adnan Tufail
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-06-19       Impact factor: 4.799

View more
  3 in total

1.  Real-Life Management of Diabetic Macular Edema with Dexamethasone Intravitreal Implant: A Retrospective Analysis of Long-Term Clinical Outcomes.

Authors:  Massimo Nicolò; Donatella Musetti; Maria Marenco; Lorenzo Cotti; Monica Bonetto; Mauro Giacomini; Carlo Enrico Traverso
Journal:  J Ophthalmol       Date:  2020-04-10       Impact factor: 1.909

2.  Intraretinal microvascular changes after ERM and ILM peeling using SSOCTA.

Authors:  Reinhard Told; Michael Georgopoulos; Gregor Sebastian Reiter; Lorenz Wassermann; Leyla Aliyeva; Lukas Baumann; Claudette Abela-Formanek; Andreas Pollreisz; Ursula Schmidt-Erfurth; Stefan Sacu
Journal:  PLoS One       Date:  2020-12-01       Impact factor: 3.240

3.  Useful field of view test performance throughout adulthood in subjects without ocular disorders.

Authors:  Karlijn Woutersen; Albert V van den Berg; F Nienke Boonstra; Thomas Theelen; Jeroen Goossens
Journal:  PLoS One       Date:  2018-05-01       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.